B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) form of Mevalonate Kinase Deficiency (MKD)

B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) form of Mevalonate Kinase Deficiency (MKD) - B7 coreceptor molecules as biomarkers in HIDS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37741

Enrollment

Registered

2012-09-20

Start date

2013-04-12

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

erfelijke autoinflammatoire ziekte hyper-IgD syndrome mevalonate kinase deficiency

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male and female individuals, 18 years of age and older, with an established diagnosis of HIDS (by molecular genetic analysis).

Exclusion criteria

Exclusion criteria: 1) the patients* inability to donate blood or urine; 2) current history of cancer, renal failure, diabetes, liver disease, thyroid diseases, major infectious diseases, or immunodeficiency; 3) pregnancy; and 4) inability to give consent.

Design outcomes

Primary

Measure	Time frame
Key data elements (outcome measures) are summarized in Table I (page 14) of the protocol. These will be quantified at each of 4 collection time points.	—

Countries

Netherlands

Outcome results